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Since the discovery of interleukin-10 (IL-10) in the 1980s, a large body of work has led to
its recognition as a pleiotropic immunomodulatory cytokine that affects both the innate
and adaptive immune systems. IL-10 is produced by a wide range of cell types, but for the
purposes of this review we shall focus on IL-10 secreted by CD4+T cells. Here we describe
the importance of IL-10 as a mediator of suppression used by both FoxP3+ and FoxP3−
T regulatory cells. Moreover, we discuss the molecular events leading to the induction of
IL-10 secretion inT helper cell subsets, where it acts as a pivotal negative feedback mecha-
nism. Finally we discuss how a greater understanding of this principle has allowed for the
design of more efficient, antigen-specific immunotherapy strategies to exploit this natural
phenomenon clinically.
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THE IMPORTANCE OF IL-10
Interleukin (IL)-10 is a pleiotropic, immunoregulatory cytokine
that is important in protecting the host from infection-associated
immunopathology, autoimmunity, and allergy. IL-10 was initially
characterized as a T helper (TH)2 specific cytokine (Fiorentino
et al., 1989); however, further investigations revealed that IL-
10 production was also associated with T regulatory (Treg) cell
responses (Moore et al., 2001; O’Garra and Vieira, 2004; Ron-
carolo et al., 2006; Sabatos-Peyton et al., 2010). It is now known
that almost all cells of both the innate and adaptive arms of the
immune system can express IL-10, including dendritic cells (DC),
macrophages,mast cells,natural killer cells (NK),eosinophils,neu-
trophils, B cells, CD8+ T cells, and TH1, TH2, and TH17 CD4+ T
cells (Maloy and Powrie, 2001; Moore et al., 2001; Fillatreau et al.,
2002; Roncarolo et al., 2006; O’Garra and Vieira, 2007; Trinchieri,
2007; Maynard and Weaver, 2008; Sabatos-Peyton et al., 2010;
Mauri and Bosma, 2012). For the purposes of this review, we will
focus on the expression of IL-10 by CD4+ T cells and how it acts
upon TH cells to promote immune homeostasis.
The first IL-10-deficient mouse model was reported 20 years
ago and in the past two decades a great deal has been learned
about the complex biology of IL-10 by studying this model (Kühn
et al., 1993). IL-10-deficient mice exhibit prolonged and exagger-
ated immune responses toward antigen, in many cases accom-
panied by excessive inflammation and tissue damage, and they
often develop chronic enterocolitis (Kühn et al., 1993; Leon et al.,
1998). This pathology is ameliorated under germ-free conditions,
suggesting a role for the gut flora in triggering disease and, there-
fore, a role for IL-10 in regulating homeostatic interactions with
commensal microorganisms (Sellon et al., 1998). Similarly, IL-
10-deficient mice develop prolonged and exacerbated fever in
response to lipopolysaccharide (LPS) (Leon et al., 1998) and suf-
fer a lethal immune response to acute infection with Toxoplasma
gondii, which is not seen in wildtype animals (Gazzinelli et al.,
1996). IL-10-deficiency also aggravates autoimmune pathology in
a range of experimental models including rheumatoid arthritis
(RA) (Hata et al., 2004), experimental autoimmune neuritis (Bai
et al., 1997), systemic lupus erythematosus (SLE) (Beebe et al.,
2002), and experimental autoimmune encephalomyelitis (EAE)
(Bettelli et al., 1998).
Several studies of human autoimmune disease have revealed
that the level of IL-10 detected in patient samples correlates
inversely with disease severity (Hajeer et al., 1998; Lim et al.,
1998; Crawley et al., 1999; Van Boxel-Dezaire et al., 1999; Gib-
son et al., 2001). In multiple sclerosis (MS) patients, low levels of
IL-10 mRNA in peripheral blood monocytes (PBMC) are asso-
ciated with relapse and with secondary progressive disease (Van
Boxel-Dezaire et al., 1999). In juvenile onset arthritis, a single-
nucleotide polymorphism (SNP) associated with reduced IL-10
mRNA expression correlates with arthritis occurring in a higher
number of joints (Crawley et al., 1999). SNPs associated with lower
IL-10 mRNA expression are also overrepresented in patients with
RA (Hajeer et al., 1998), severe asthma (Lim et al., 1998), and SLE
(Gibson et al., 2001).
Together, these studies in mouse and man demonstrate the
importance of IL-10 in immune regulation and the impact of
IL-10 dysregulation on a wide range of disease states.
THYMICALLY AND PERIPHERALLY GENERATED FoxP3+
REGULATORY T CELLS SECRETE IL-10
Regulatory T cells expressing the master transcription factor
forkhead box P3 (FoxP3) are essential for immune homeosta-
sis (Chaudhry and Rudensky, 2013). Loss of function muta-
tions within the Foxp3 locus result in congenital Treg deficiency
and severe systemic immunopathology in both man (Gambineri
et al., 2003) and mouse (Brunkow et al., 2001). Natural, or
thymic, Foxp3+ Tregs (tTreg) develop during selection against
self-antigen in the thymus (Fontenot et al., 2003), whereas periph-
erally induced Foxp3+ Tregs (pTreg) develop extrathymically in
response to antigen-specific stimulation in the presence of trans-
forming growth factor beta (TGF-β) (Curotto de Lafaille et al.,
2004). tTregs are implicated in tolerance to self-antigens (Hori
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et al., 2003), whilst pTregs appear to modulate immune responses
against both self-antigens not expressed in the thymus and foreign
antigens (Pacholczyk et al., 2006; Josefowicz et al., 2012; Samstein
et al., 2012). Although several groups have attempted to define a
phenotype which distinguishes tTreg and pTreg (Thornton et al.,
2010; Weiss et al., 2012; Yadav et al., 2012), at the time of writing,
no molecular markers have been identified that can adequately dis-
criminate these two types of Foxp3+ Treg cells, especially under
inflammatory conditions (Verhagen and Wraith, 2010; Gottschalk
et al., 2012; Weiss et al., 2012; Himmel et al., 2013).
FoxP3+ Tregs are able to secrete IL-10 and this appears to
be particularly important in regulating immune responses at the
body’s environmental interfaces (Uhlig et al., 2006; Maynard et al.,
2007; Rubtsov et al., 2008). Mice with selective knockout of IL-10
in Foxp3-expressing cells (IL-10fl/fl× FoxP3-cre) do not develop
spontaneous systemic autoimmunity but do develop spontaneous
colitis in a similar manner to germline IL-10-knockout ani-
mals (Rubtsov et al., 2008). These mice also develop heightened
lung inflammation following intranasal challenge with ovalbumin
(OVA), characterized by increased IL-5, IL-13, and interferon-
gamma (IFN-γ) mRNA in lung tissue (Rubtsov et al., 2008).
IL-10fl/fl× FoxP3-cre mice exhibit exacerbated skin hypersensi-
tivity when challenged with dinitrofluorobenzene (Chang et al.,
2002). The secretion of IL-10 by FoxP3+ Treg cells is also impor-
tant in regulating immune responses against self-antigens in some
animal models. In the non-obese diabetic (NOD) mouse model
of Type 1 diabetes, disease progression is associated with gradual
loss of pancreatic IL-10-secreting FoxP3+ Tregs (Kornete et al.,
2012). In this model, inducible T cell costimulator (ICOS) block-
ade results in reduced IL-10 secretion by ICOS+ FoxP3+ Tregs
and this is associated with exacerbated diabetes (Kornete et al.,
2012). Regulation of murine TH17 responses by FoxP3+ Tregs
is dependent upon a Treg-specific IL-10-induced transcriptional
program, which includes signal transducers and activators of tran-
scription (STAT)3 dependent induction of Treg-derived IL-10
(Chaudhry et al., 2011). Selective deletion of IL-10RA on FoxP3+
Tregs reduces their expression of IL-10 and renders them unable
to prevent IL-17-mediated pathology (Chaudhry et al., 2011).
FoxP3− REGULATORY T CELLS SECRETE IL-10
Following stimulation under specific conditions, naïve CD4+ T
cells can differentiate into a population of FoxP3−, IL-10-secreting
T cells with potent regulatory capacity (Groux et al., 1997). Often
termed type 1 regulatory T cells (Tr1), they are characterized by
the expression of high levels of IL-10, sometimes concomitant with
IL-5 or IFN-γ, and low expression of IL-2 and IL-4 (Groux et al.,
1997). A recent study found that Tr1 cells can be identified by
CD49b and LAG-3 expression in both human and mice (Gagliani
et al., 2013). Tr1 cells can be generated in vitro from naïve human
and murine CD4+ T cells by various methods, including repeated
T cell receptor (TCR) stimulation in the presence of high con-
centrations of exogenous IL-10 (Groux et al., 1997). In in vitro
cultures, antigen-presenting cells (APC) are required to generate
Tr1 cells from IL-10 treated naïve CD4+ T cells (Gregori et al.,
2010). This suggests that IL-10 does not act directly upon naïve
CD4+ T cells but rather upon APC to render them able to promote
Tr1 induction.
In man, a subset of peripheral blood DC, termed DC-10, and
characterized by secretion of relatively high amounts of IL-10 and
low amounts of IL-12, are particularly able to induce the devel-
opment of Tr1-like cells in vitro (Gregori et al., 2010). DCs with a
similar phenotype to DC-10 cells can also be generated in vitro by
culturing human monocytes with IL-4, granulocyte macrophage
colony-stimulating factor (GM-CSF) and IL-10 (Gregori et al.,
2010). These in vitro-generated DC-10-like cells have compara-
ble function and phenotype to those isolated from peripheral
blood and may provide a method for the induction of IL-10-
secreting T cells for use therapeutically (Gregori et al., 2010).
Expression of human leukocyte antigen (HLA)-G and a ligand
for the shed extracellular portion of HLA-G, immunoglobulin-
like transcript 4 (ILT-4 or LILRB2), are upregulated by IL-10
and have been used to identify a subset of tolerogenic DC in
man (Allan et al., 1999; Manavalan et al., 2003; LeMaoult et al.,
2004; Gregori et al., 2010). This suggests that IL-10-induced
interactions between soluble HLA-G and DC-localized ILT-4, in
subsets of DCs including DC-10 cells, is required to induce IL-10-
secreting CD4+ T cells from naïve CD4+ T cells (Gregori et al.,
2010).
In the mouse, IL-27 has been shown to induce Tr1-like cells
from naïve CD4+ T cells in vitro (Awasthi et al., 2007). IL-27
induces expression of c-Maf and IL-21 which, in combination
with ICOS receptor ligation, act to promote Tr1 differentiation
(Awasthi et al., 2007; Pot et al., 2009). In addition, IL-27 also
upregulates the aryl hydrocarbon receptor (AhR) which, when
ligated, synergizes with c-Maf to drive IL-10 expression (Apetoh
et al., 2010). The secretion of IL-21 by Tr1-like cells can further
induce c-Maf expression and, thus, may form an autocrine posi-
tive feedback loop promoting IL-10 induction (Pot et al., 2009).
Murine DCs can be induced to secrete IL-27 by treatment with
recombinant galectin-1. Galectin-1-treated DCs can induce Tr1-
like cells in vitro, dampen myelin oligodendrocyte glycoprotein
(MOG35-55)-induced EAE and antigen-specific proliferation of
splenocytes (Ilarregui et al., 2009). Endogenous expression of
galectin-1 in DCs is upregulated by IL-10, 1,25(OH)2-vitamin
D3 (VitD3), and galectin-1 itself (Ilarregui et al., 2009; Cedeno-
Laurent et al., 2012). Together these data highlight the importance
of the APC in IL-10 induction in naïve CD4+ T cells in many
experimental models.
In man, naïve CD4+ T cells can be directed to secrete IL-10,
independent of APC, by co-ligation of the TCR and the comple-
ment receptor CD46 with either the native ligand, C3b, or with
anti-CD46 antibodies (Kemper et al., 2003; Cardone et al., 2010).
The importance of this pathway is reinforced by the observation
that CD4+ T cells isolated from MS and RA patients demonstrate
defective IL-10 secretion in response to stimulation with anti-CD3
and -CD46 antibodies (Astier et al., 2006; Cardone et al., 2010).
Ligation of CD46 leads to robust phosphorylation of extracellular
signal related kinase 1 and 2 (ERK1/2) which, as will be discussed in
more detail below, is a prerequisite for IL-10 expression in CD4+ T
cells (Zaffran et al., 2001). CD46 is not expressed by murine T cells,
limiting the potential to study the role of CD46 in vivo, but trans-
genic expression of human CD46 in mice leads to elevated serum
IL-10 levels following Neisseria meningitides infection (Johansson
et al., 2005).
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Tr1-like cells can also be induced in the absence of APC by
stimulating naïve murine CD4+ T cells with anti-CD3 and -CD28
antibodies in the presence of VitD3, dexamethasone (Dex), and
anti-IFN-γ, -IL-4 and -IL-12 antibodies (Barrat et al., 2002). Neu-
tralization of IL-10 in the culture medium inhibits development
of Tr1 cells (Barrat et al., 2002). In vivo, Tr1 cells can be generated
by immunizing mice with cholera toxin (Lavelle et al., 2003, 2004)
or treatment with rapamycin and IL-10 (Battaglia et al., 2006).
SELF-LIMITATION OF T HELPER CELLS BY IL-10 SECRETION
Deviation from normal immune homeostasis, during infection or
other insult, will result in tissue damage if allowed to persist fol-
lowing elimination of the target antigen. Similarly, in situations
of chronic antigen exposure, such as at mucosal surfaces and in
relation to self-antigen, it is essential that regulatory mechanisms
exist to restore effector CD4+ T cell homeostasis. In addition
to the regulatory effects of FoxP3+ and FoxP3− Tregs, an IL-
10-dependent negative feedback loop is important in protecting
tissues from T cell-mediated autoimmune disease and infection-
driven immunopathology. For example, wildtype C57BL/6 mice,
when primed with MOG in complete Freund’s adjuvant (CFA),
develop EAE associated with TH1 and TH17 cytokines, but recover
rapidly (Bettelli et al., 1998). In contrast, IL-10-deficient mice do
not recover and develop a progressive form of EAE (Bettelli et al.,
1998).
TH17-DERIVED IL-10 IN THE REGULATION OF TH17
RESPONSES
TH17 cells are strongly implicated in many autoimmune con-
ditions traditionally thought to be solely TH1-mediated (Stein-
man, 2007). TH17 cells produce IL-17A and IL-17F, which can
be detected in target tissues of patients with RA, MS, and SLE
(Matusevicius et al., 1999; Linden et al., 2000; Wong et al., 2000;
Hashimoto et al., 2005). Experimental colitis, induced by adoptive
transfer of IL-17-secreting CD4+ T cells to Rag-deficient mice,
can be suppressed by the co-transfer of IL-10-secreting CD4+
T cells (Huber et al., 2011). This suppressive effect is depen-
dent on expression of the IL-10 receptor (IL-10R) by the IL-17-
secreting CD4+ T cells (Huber et al., 2011). This implies that IL-10
can directly attenuate the pathogenicity of IL-17-secreting CD4+
T cells.
TH17 cells have a developmental pathway that overlaps with
FoxP3+ iTregs (Bettelli et al., 2006). Culturing naïve CD4+ T
cells with TGF-β alone drives the generation of FoxP3+ iTregs
but in combination with the inflammatory cytokine IL-6 gener-
ates TH17 cells which express RoRγt and secrete IL-17 (Figure 1)
(Ivanov et al., 2006; McGeachy et al., 2007, 2009). In murine
transfer experiments, IL-6- and TGF-β-generated TH17 cells failed
to induce EAE; in contrast, TH17 cells cultured with IL-23
were encephalitogenic (Figure 1) (McGeachy et al., 2007). This
correlates with enhanced expression of IL-10 in TH17-polarized
FIGURE 1 | In response to IL-6,TGF-β, andTCR stimulation naïve
CD4+ cells upregulate RoRγt and c-Maf transcription factors and
develop intoTH17 polarized naïve CD4+ cells which secrete IL-17
and IL-10 (McGeachy et al., 2007). In the presence of IL-6, TGF-β, IL-23,
and TCR stimulation, naïve CD4+ cells differentiate into effector TH17
cells which express RoRγt and secrete IL-17 and GM-CSF (McGeachy
et al., 2009). In response to Staphylococcus aureus, effector TH17 cells
develop into CCR6+ CCR4+ memory cells which secrete IL-17A and
IL-10; *however, it is unclear if c-Maf regulates IL-10 in these cells
(Metzler and Wraith, 1993; Zielinski et al., 2012). TH17 cells express the
IL-10 receptor and can therefore self-regulate (Stumhofer et al., 2007;
Huber et al., 2011). IL-1β can down regulate IL-10 expression from both
TH17 polarized naïve CD4+ cells and TH17 memory cells (Zielinski et al.,
2012).
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CD4+ T cells cultured in the absence of IL-23 (McGeachy et al.,
2007).
Interleukin-10-secreting TH17-polarized CD4+ T cells have
also been observed with defined pathogen specificity. Upon res-
timulation in vitro, human Staphylococcus aureus-specific TH17
cells secreted IL-10 in combination with IL-17A (Figure 1) (Zielin-
ski et al., 2012). In contrast, Candida albicans-specific TH17-
polarized CD4+ T cells did not secrete IL-10 and instead secreted
IFN-γ concomitant with IL-17A (Zielinski et al., 2012). IL-10
secretion by naïve CD4+ T cells polarized toward IL-17 secretion
or by CCR6+CCR4+ memory TH17 cells was inhibited by IL-1β
(Figure 1) (Zielinski et al., 2012). Cryopyrin associated periodic
syndrome (CAPS) is an autoinflammatory disease characterized
by excessive production of IL-1β (77). IL-10 production is sig-
nificantly inhibited in TH17 cell clones from CAPS patients but
in vivo administration of Anakinra, an IL-1R1 antagonist, restores
IL-10 secretion by IL-17A+ T cell clones (Jacobs and Ciaccio, 2010;
Zielinski et al., 2012). Together these studies suggest that IL-10
production by IL-17A-secreting CD4+ T cells may refine TH17
responses to target them toward specific pathogens. In addition,
these results show that the lack of IL-10 secretion by TH17 cells
is associated with autoinflammatory conditions, highlighting the
importance of effector T cell-derived IL-10 in immune regulation.
TH1-DERIVED IL-10 IN THE REGULATION OF TH1 RESPONSES
TH1 cells, characterized by expression of the transcription factor
T-bet and secretion of IFN-γ, play a central role in the clearance
of intracellular pathogens (Romagnani, 1996). However, they are
also responsible for mediating immune pathology and autoim-
mune disease in a number of settings. For example, the intra-
cellular protozoan parasite T. gondii elicits an IL-12-dependent
TH1 response which is important for controlling its replication
in infected mice (Gazzinelli et al., 1994). In IL-10-deficient mice,
this TH1 response is exacerbated and results in severe cytokine-
associated immunopathology and mice succumb to disease even
though parasitic growth is effectively restricted (Gazzinelli et al.,
1996). This immune pathology is characterized by increased secre-
tion of TH1 cytokines, expression of acute inflammatory markers
and necrotic tissue damage (Gazzinelli et al., 1996). A dysregulated
TH1 response and subsequent tissue damage are also observed
in IL-10-deficient mice following infection with other pathogens,
including Leishmania major (Anderson et al., 2007), Trypanosoma
cruzi (Abrahamsohn and Coffman, 1996; Hunter et al., 1997),
Plasmodium chabaudi (Linke et al., 1996), Listeria monocytogenes
(Deckert et al., 2001), murine cytomegalovirus (Oakley et al.,
2008), and respiratory influenza virus (Sun et al., 2009). Similarly,
IL-10-dependent TH1 self-regulation is essential in restraining
the immune response and preventing tissue damage in models
of autoimmune disease including colitis (Suri-Payer and Cantor,
2001), RA (Hata et al., 2004), neuritis (Bai et al., 1997), SLE (Beebe
et al., 2002), and uveoretinitis (Rizzo et al., 1998). Conversely,
CD4+ T cells which co-secrete IFN-γ and IL-10 can be isolated
from patients with chronic infections, including Mycobacterium
tuberculosis and Leishmania donovani (Gerosa et al., 1999; Kemp
et al., 1999; Boussiotis et al., 2000). This suggests that IL-10 secre-
tion by TH1-like cells regulates the anti-pathogen response and
prevents clearance.
Interleukin-10-secreting, TH1-like cells can be induced in
experimental models by repeated or chronic administration of
antigen (Figure 2) (Metzler and Wraith, 1993; Gabryšová et al.,
2009; Gabryšová and Wraith, 2010). In the Tg4 TCR-transgenic
mouse model, repeated intranasal (i.n.) administration of analogs
of the Ac1-9 peptide of myelin basic protein drives the generation
of FoxP3− T-bet+ IL-10-secreting CD4+ T cells which protect
animals from EAE (Rogge et al., 1997; Burkhart et al., 1999;
Gabryšová et al., 2009). IL-10 secreted by T-bet+ CD4+ T cells
modulates DC function, inducing downregulation of MHC class
II, the co-stimulatory molecules CD80, CD86, and CD40, and the
TH1-promoting cytokine IL-12 (Moore et al., 2001; Gabryšová
et al., 2009). This renders DCs from Tg4 mice treated repeatedly
with the Ac1-9 analog less effective than DCs from non-peptide
treated mice at priming naïve CD4+ T cells and promoting TH1
differentiation (Gabryšová et al., 2009). This represents a thera-
peutically exploitable negative feedback loop for the attenuation
of IFN-γ-driven inflammatory responses (Figure 2).
Although IL-10-mediated negative feedback regulation of
CD4+ effector lymphocyte responses undoubtedly evolved to
prevent collateral tissue damage during immune responses to
pathogens, it can also prevent successful clearance of microorgan-
isms and lead to prolonged chronic infection. For example, in mice
infected with L. major, CD4+ Foxp3− IL-10-secreting cells are
associated with development of contained, chronic, non-healing
lesions (Anderson et al., 2007). Elevated CD4+ T cell-derived IL-10
also correlates with an inability to effectively clear M. tubercu-
losis (Redford et al., 2011), L. monocytogenes (Dai et al., 1997),
Mycobacterium leprae (Sieling et al., 1993), and transformed cells,
for example squamous cell carcinomas (Kim et al., 1995).
TH2-DERIVED IL-10 IN THE REGULATION OF TH2 RESPONSES
The cytokines IL-4, IL-5, and IL-13, secreted by TH2 cells, provide
protective immunity in the context of parasite infection (Kore-
naga et al., 1991; Urban et al., 1991), but also initiate, amplify, and
prolong allergic responses by enhancing production of IgE and
are responsible for recruitment, expansion, and differentiation of
eosinophils and mast cells (Robinson et al., 1992; Romagnani,
1994; Umetsu and DeKruyff, 1997, 1999; Northrop et al., 2006).
Early studies of experimental TH2-inducing parasitic infections,
including Trichuris muris and T. cruzii demonstrated a key role for
IL-10 in preventing a lethal T cell response (Silva et al., 1992; Bar-
bosa de Oliveira et al., 1996; Schopf et al., 2002). The exaggerated
cytokine response observed in IL-10-deficient mice was initially
assumed to be due to a requirement for IL-10 in antagonizing dele-
terious TH1 responses (Silva et al., 1992; Barbosa de Oliveira et al.,
1996; Schopf et al., 2002). More recently, it has become clear that
TH2-derived IL-10 is also associated with downregulation of IL-4
and IL-13 during allergic responses (Grünig et al., 1997; Jutel et al.,
2003; Akdis et al., 2004). In a mouse model of allergic bronchopul-
monary aspergillosis, IL-10 is crucial in restraining TH2 responses
(Grünig et al., 1997). After repeated inhalation of Aspergillus fumi-
gatus allergens, lung cells and broncho-alveolar lavage (BAL) fluid
from IL-10-knockout mice produced higher levels of IL-4, IL-5,
and IFN-γ, leading to exaggerated airway inflammation (Grünig
et al., 1997). In addition, alveolar macrophages isolated from asth-
matic patients secrete lower levels of IL-10 compared to those from
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FIGURE 2 | In response to either IL-12 or IL-4 andTCR stimulation
naïve CD4+ T cells will upregulateT-bet or GATA3 transcription
factors respectively. Differentiation of naïve CD4+ t cells into TH1/TH2
lineages is based on T-bet/GATA3 transcription factor expression
(Ouyang et al., 2000; Lucas et al., 2003). Upon repeated chronic TCR
stimulation TH1 and TH2 cells express IL-10 (Gabryšová et al., 2009; Xu
et al., 2009). In TH1 cells, IL-10 expression is regulated by NFIL3 and
correlates with c-Maf expression (Kim et al., 1999; Saraiva et al., 2009).
In TH2 cells, IL-10 expression is regulated by NFIL3 (Motomura et al.,
2011). IL-10 secreted by TH1/TH2 cells can inhibit further naïve CD4+
differentiation by inhibiting IL-12/IL-4 and DC function (Moore et al.,
2001; Taylor et al., 2007, 2009).
non-asthmatics (Borish, 1998; John et al., 1998). In healthy bee
keepers, regular bee venom exposure elicits a regulatory response
characterized by antigen-specific IL-10 secretion and a reduction
in IL-4 and IL-13 production over the course of the bee season
(Meiler et al., 2008). TGF-β appears to play a minor role in the
effect and little increase in FoxP3 expression is observed after bee
venom exposure, suggesting that repeatedly activated allergen-
specific T cells, and not FoxP3+ Tregs induced de novo, are the
source of regulatory IL-10 (Meiler et al., 2008).
In mouse models of allergy, it is clear that IL-10 plays an
important role in mediating successful antigen-specific thera-
peutic tolerance. For example, intranasal administration of pep-
tide derived from OVA can reduce symptoms of TH2-driven
OVA/alum-induced airway hypersensitivity (AHR) (Akbari et al.,
2001). Protection from AHR is associated with induction of IL-
10-secreting pulmonary DCs with capacity to induce IL-4 and
IL-10-secreting OVA-specific CD4+ T cells in vitro (Akbari et al.,
2001). In addition, adoptive transfer of DCs from i.n. OVA treated
mice to naïve animals induced OVA-specific CD4+ T cell unre-
sponsiveness in recipients. Transfer of IL-10-deficient DCs does
not induce tolerance in recipient mice (Akbari et al., 2001). Simi-
larly, neutralization of IL-10 during tolerance induction results in
elevated OVA-specific IgE production and negates the protective
effect of OVA administration (Vissers et al., 2004). Successful
allergen-specific immunotherapy (SIT) in man, for example in
the treatment of grass pollen or house dust mite allergies, corre-
lates with generation of IL-10-secreting CD4+ T cells (Francis
et al., 2003; Jutel et al., 2003). IL-10 limits TH2 responses by
downregulation of IL-4, inhibition of antigen presentation by
MHC class II on DCs, and suppression of co-stimulatory mol-
ecule expression including CD28, ICOS, and CD2 (Taylor et al.,
2007, 2009). This is mediated via src homology phosphatase
(SHP)-1 in naïve CD4+ T cells, suggesting that IL-10 can reg-
ulate effector responses and also prevent the differentiation of
TH2 cells from naïve CD4+ T cells (Figure 2) (Taylor et al.,
2007).
TRANSCRIPTIONAL REGULATION OF IL-10 IN TH1, TH2, TH17,
AND Tr1 CELLS
As described above, IL-10 can be secreted by different CD4+ T cell
types, each characterized by a distinct developmental program and
hallmark transcription factors. However, some signaling pathways
and transcription factors required to induce IL-10 expression are
shared between CD4+ effector T cell subsets. The group of tran-
scription factors regulating IL-10 transcription in all cell types has
been reviewed recently (Saraiva and O’Garra, 2010) and we will
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focus on IL-10 transcriptional regulation in TH1, TH2, TH17, and
Tr1 cells.
ERK1 and ERK2 activation is required for IL-10 expression
in TH1, TH2, and TH17 cells (Saraiva et al., 2009). In CD4+
T cells, the strength of signaling through the TCR is propor-
tional to ERK1 and ERK2 activation and thus to IL-10 expression
(Saraiva et al., 2009). Specifically, in Th1 cells high-level TCR
stimulation leads to enhanced and prolonged ERK1 and ERK2
phosphorylation which, in combination with IL-12-driven signal-
ing through STAT4, promotes induction of IL-10 (Saraiva et al.,
2009).
Recently differentiated TH1 cells do not secrete IL-10 and have
an IL-10 promoter which is inaccessible to DNase 1 and thus not
permissive for transcription (Im et al., 2004). In contrast, fully dif-
ferentiated TH2 cells have an open, euchromatic IL-10 promoter
(Im et al., 2004). In addition, histone modifications which corre-
late with active gene expression; histone 3 lysine 4 dimethylation
(H3K4me2) and histone 4 acetylation (AcH4) are associated with
the IL-10 promoter in effector TH2 cells but not TH1 cells (Im
et al., 2004).
TH2 effector differentiation and function is classically described
as being dependent upon STAT6-induced GATA3 expression
(Shoemaker et al., 2006). Although STAT6-induced GATA3 is
thought to mediate the epigenetic changes that result in an open
IL-10 locus in TH2 cells, both proteins are dispensable for IL-
10 secretion in mature TH2-polarized CD4+ T cells (Figure 3)
(Ouyang et al., 2000; Shoemaker et al., 2006). Similarly, c-Maf is
another transcription factor originally associated with TH2 cells
although it is not required for IL-10 production in CD4+ T cells
cultured under TH2-polarizing culture conditions (Kim et al.,
1999). Interestingly, in non-polarizing culture conditions, where
cells secreted IFN-γ, IL-10 production was dependent on c-Maf
expression (Kim et al., 1999). Indeed, c-Maf binds to the Maf-
recognition element within the IL-10 promoter and is required for
IL-10 expression in Tr1, TH17, and possibly TH1 cells (Figure 3)
(Kim et al., 1999; Pot et al., 2009; Saraiva et al., 2009; Xu et al.,
FIGURE 3 | InTH1 cells IL-10 expression is induced by IL-12-STAT4
and IL-27-STAT1 pathways, possibly through c-Maf and NFIL3
(Saraiva et al., 2009). In TH2 cells IL-10 expression is induced by
IL-4-STAT6 through GATA3 (imprinting and chromatin modification) and
NFIL3 (Shoemaker et al., 2006; Motomura et al., 2011). In TH17 cells
IL-10 expression is induced by IL-6/TGF-β-STAT3 through c-Maf (Xu et al.,
2009). In Tr1 cells, IL-10 is induced by IL-27 and AhR through induction
of C-Maf (Pot et al., 2009; Apetoh et al., 2010). *c-Maf is correlated with
IL-10 expression in TH1 cells (Saraiva et al., 2009). In non-polarizing
culture conditions, IL-10 expression is dependent on c-Maf (Kim et al.,
1999). Whether c-Maf binds to the IL-10 locus in TH1 cells is unknown.
**NFIL3-deficient TH1 cells do not express IL-10 on repetitive
stimulation, but NFIL3 has not been observed bound to the IL-10 locus
in TH1 cells. (Motomura et al., 2011).
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2009). Although c-Maf is required for IL-10 secretion by a vari-
ety of CD4+ T cell lineages, differences in the pathways which
evoke c-Maf expression reflect the diversity of the TH lineages.
In TH1 cells, IL-10 expression can be induced by both IL-27 via
both STAT1 and STAT3 and IL-12 via STAT4 (Stumhofer et al.,
2007; Saraiva et al., 2009). In Tr1 cells, IL-27 induces expression of
c-Maf and AhR, presumably through STAT1, which cooperatively
promote IL-10 expression (Figure 3) (Pot et al., 2009; Apetoh et al.,
2010). In TH17 cells, c-Maf expression is induced by the synergistic
action of TGF-β and IL-6 via STAT3 and, in contrast to the obser-
vations in TH1 cells, the activation of STAT1 is antagonistic for
c-Maf-induced IL-10 expression in TH17-polarized CD4+ T cells
(Figure 3) (Xu et al., 2009). Which pathway drives c-Maf expres-
sion may depend on specific conditions such as the affinity and
dose of antigen (Saraiva et al., 2009). For example, in TH1 cells,
IL-12-mediated STAT4 signaling only promotes IL-10 production
in combination with high-level TCR stimulation (Saraiva et al.,
2009) whereas at lower levels of TCR stimulation, the same stimu-
lus induces the development of IFN-γ-secreting TH1 cells that do
not express IL-10 (Morinobu et al., 2002; Lucas et al., 2003; Saraiva
et al., 2009).
The basic leucine zipper transcription factor nuclear factor IL-
3-regulated (NFIL3 or E4BP4) has recently been shown to play a
role in a range of immunological processes (reviewed in Male et al.,
2012). NFIL3-deficient TH2 cells and FoxP3+ Tregs are defective in
IL-10 secretion and it is also required for the upregulation of IL-10
in repeatedly stimulated TH1 cells (Figure 3) (Chang et al., 2007;
Motomura et al., 2011). NFIL3 does not bind to the IL10 promoter,
but rather to introns within the coding region of the locus (Moto-
mura et al., 2011). In NFIL3-deficient TH2 cells, these regions
are heterochromatic and inaccessible, suggesting that NFIL3 may
play a role in remodeling the IL10 locus to permit transcription
(Motomura et al., 2011). Upregulation of NFIL3 in TH2 cells is
dependent on IL-4 and STAT6, even upon GATA3 overexpression
(Kubo and Motomura, 2012). Further work is required to under-
stand the pathways leading to induction of NFIL3 expression in
repeatedly stimulated TH1 cells and to confirm that NFIL3 is a
universal regulator of IL-10 expression in CD4+ T cells.
CLINICAL APPLICATIONS AND FUTURE PROSPECTS
As described above, the ratio of secreted IL-10 to the secretion of
the relevant effector cytokine (IFN-γ, IL-4, or IL-17) can dictate
the outcome of a polarized CD4+ T cell response and, therefore,
the likelihood of an effective immune response and the potential
for tissue damage, through hyper- or hypo-immune activation.
These observations have made IL-10 an attractive therapeutic tar-
get for intervention in a wide range of human conditions including
autoimmunity, cancer, and persistent infection (O’Garra et al.,
2008).
Inhaled glucocorticoids are at present the treatment of choice
for asthma and severe allergic conditions. In addition to the effects
of corticosteroids, including dexamethosone, on IL-10 expres-
sion in vitro, glucocorticoid administration to asthmatic patients
enhances IL-10 production concomitant with a reduction in TH1
and TH2 effector cytokines (John et al., 1998; Richards et al.,
2000). Treatment with inhaled steroids is also accompanied by
expansion of CD4+ CD25+ Treg populations and upregulation
of Foxp3 gene expression in CD4+ T cells isolated from PBMCs
(Karagiannidis et al., 2004). Furthermore, failure to upregulate
IL-10 in response to steroid exposure correlates with steroid resis-
tant disease (Hawrylowicz et al., 2002; Xystrakis et al., 2006). This
further illustrates the importance of steroid-induced IL-10 in the
treatment of asthma and atopy.
Several pre-clinical cancer models suggest that IL-10 acts as a
negative mediator of anti-tumor immunity (Halak et al., 1999;
Garcia-Hernandez et al., 2002; Yang and Lattime, 2003). These are
further supported by human studies in Hodgkin’s lymphoma, B
cell lymphoma, melanoma, and hepatocellular carcinoma, where
elevated serum IL-10 levels correlate with poor survival (Bohlen
et al., 2000; Chau et al., 2000; Nemunaitis et al., 2001; Lech-
Maranda et al., 2004). These observations have supported pro-
posals that blockade of IL-10R signaling may be a beneficial
adjunct therapy in the oncology clinic. However, the pleiotropic
role of IL-10 has resulted in several paradoxical observations.
For example, studies investigating IL-10 levels in non-small cell
lung cancer observed that higher IL-10 expression correlated with
better survival (Gonzalez-Aragoneses et al., 2007). In addition,
overexpression of IL-10 within tumors, in murine carcinoma and
melanoma models, results in loss of tumorigenicity accompa-
nied by an enhanced lymphocyte response (Giovarelli et al., 1995;
Gerard et al., 1996; Zheng et al., 1996; Adris et al., 1999). IL-10-
mediated prevention of tumor growth is dependent on T cells
and/or NK cells as these effects are abrogated in immunodeficient
mice (Giovarelli et al., 1995; Zheng et al., 1996). In agreement with
these reports, IL-10 can stimulate NK cell and alloreactive CD8+
T cell responses in vitro and in vivo and may have the same effect
in certain cancers or subsets of patients (Groux et al., 1998, 1999;
Cai et al., 1999; Micallef et al., 1999; Lauw et al., 2000).
Systemic administration of recombinant IL-10 has been trialed
in patients with psoriasis and Crohn’s disease and for the alle-
viation of post-operative inflammation (Colombel et al., 2001;
Reich et al., 2001; O’Garra et al., 2008). This has been gener-
ally tolerated at moderate doses and has provided some clinical
improvement in psoriasis patients, associated with a reduction in
TH1 cytokines (Reich et al., 2001). However, side effects includ-
ing fever and headaches were observed and, in Crohn’s disease
patients, IL-10 administration led to elevated serum levels of IFN-
γ and no improvement in disease symptoms (Tilg et al., 2002).
Simultaneous administration of IL-10 and LPS in healthy volun-
teers similarly led to an exaggerated TH1-like response compared
to LPS alone (Lauw et al., 2000). This reinforced the potential for
IL-10 to play a proinflammatory role, particularly at high doses,
and made the use of recombinant IL-10 as a therapeutic approach
unfavorable.
The failure of systemic IL-10 administration to ameliorate TH1-
mediated pathologies highlights the importance of refinement and
specificity in the design of immunomodulatory therapy. Target-
ing IL-10-inducing interventions to a particular anatomical site,
or to cells with defined antigen specificity, may prove far more
effective than non-targeted therapies. For example, although sys-
temic administration of IL-10 can only partially ameliorate EAE
symptoms in mice (Cannella et al., 1996; Nagelkerken et al., 1997),
targeted expression of IL-10 in either CD2 or MHC-II-expressing
cells completely abrogates disease (Bettelli et al., 1998; Cua et al.,
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1999). Similarly, expression of IL-10 in the central nervous system
(CNS) rendered mice resistant to EAE whereas the cytokine, intro-
duced systemically using the same expression vector, provided
little benefit (Cua et al., 2001). Interestingly, orally administered
IL-10, given with low-dose MBP peptide, prevented EAE (Slavin
et al., 2001). Expression of IL-10 under control of the IL-2 pro-
moter in proteolipid protein (PLP)-specific CD4+ T cells renders
them able to both prevent and treat EAE thereby demonstrating
the efficacy of antigen-specific IL-10 induction (Mathisen et al.,
1997). Similarly, studies of IL-10-secreting cell-based therapies
have reinforced the advantage of antigen specificity for effective
immunotherapy (Barrat et al., 2002). As described above, IL-10-
secreting CD4+ T cells can be derived from naïve T cells following
in vitro treatment with Dex and VitD3 (Barrat et al., 2002). In
theory, this would provide a source of cells that could be used
therapeutically. Using OVA-specific TCR-transgenic (DO11.10) T
cells, it was demonstrated that, although IL-10-secreting CD4+ T
cells can be generated using anti-CD3 and -CD28 polyclonal stim-
ulation, antigen-specific stimulation is required in vivo for IL-10-
secreting cells to prevent EAE following adoptive transfer (Barrat
et al., 2002). This makes antigen-SIT a very attractive approach
to realize the potential of IL-10 modulation in the treatment of
autoimmune diseases.
Autoantigen- and allergen-SIT aim to restore appropriate
immune responses to innocuous antigens while avoiding systemic
immune suppression thus preserving host-protective immunity
(reviewed in Miller et al., 2007; Sabatos-Peyton et al., 2010). A vari-
ety of strategies have emerged; some attempt to induce antigen-
specific FoxP3+ pTregs, others to induce a “switch” between TH1
and TH2-dominated immune responses or to force effector CD4+
T cells toward a terminally differentiated, IL-10-secreting pheno-
type (Miller et al., 2007; Sabatos-Peyton et al., 2010). Regardless
of the cellular mechanisms underlying the SIT, successful ther-
apies are almost always associated with an increase in specific,
antigen-induced IL-10 (Miller et al., 2007; O’Garra et al., 2008;
Sabatos-Peyton et al., 2010). Antigen-SIT has proven effective in
many pre-clinical models of autoimmune disease, for example
EAE and the NOD diabetes model (Metzler and Wraith, 1993;
Brocke et al., 1996; Tian et al., 1996; Burkhart et al., 1999; Shoda
et al., 2005; Gabryšová et al., 2009; Gabryšová and Wraith, 2010;
Schall et al., 2012). Translation of these therapies into the clinic has
shown some efficacy in treatment of MS (Warren et al., 2006), RA
(Prakken et al., 2004), SLE (Muller et al., 2008), and T1D (Thrower
et al., 2009; Hjorth et al., 2011; Ludvigsson et al., 2012). For exam-
ple, in a phase 1 clinical trial in T1D patients using an epitope of
proinsulin (C19-A3), treatment resulted in increased serum IL-10
levels and improved glycemic control in the group which received
10µg of peptide (Thrower et al., 2009). Interestingly, a higher dose
of 100µg did not show any beneficial clinical effect and no increase
in serum IL-10 (Thrower et al., 2009).
These studies demonstrate that, when appropriately designed,
SIT is safe in man and has great potential in treating a wide range
of autoimmune and allergic diseases. However, further research
is required to determine suitable routes of administration and to
refine dosing strategies. Inappropriate antigen dosing, in partic-
ular, can lead to hypersensitivity reactions or to a lack of efficacy
(Bielekova et al., 2000; Kappos et al., 2000). Administration of an
escalating series of antigen doses has been widely employed in the
field of allergen-SIT and this approach being increasingly adopted
in autoantigen-SIT (Sabatos-Peyton et al., 2010).
In many autoimmune conditions, the antigen and immun-
odominant epitopes are uncharacterized, and where they are char-
acterized, epitope spreading can lead to polyantigenic responses
within a single patient (Miller et al., 2007; Sabatos-Peyton et al.,
2010). This provides further challenges for the successful trans-
lation of SIT from (often monoclonal, TCR-transgenic) animal
models to heterogenous groups of patients. Clearly, successful
translation of this approach will rely on the ability of a therapeutic
strategy to induce “bystander suppression” whereby T cells spe-
cific for epitopes within antigen A are capable of suppressing the
response of T cells specific for antigens B, C, D, etc. within the same
tissue. The fact that IL-10 suppresses co-stimulatory molecule
expression by APC explains why IL-10 treated APC can medi-
ate bystander suppression and why strategies designed to induce
IL-10 are required for effective SIT. It will also be essential to
widen our understanding of the molecular mechanisms underly-
ing successful SIT, enabling development of adjunct therapies and
adjuvants to bolster efficacy, improve safety, and aid maintenance
of long-term tolerance.
In conclusion, IL-10 plays an essential and highly complex role
in the modulation of adaptive immune responses. The pleiotropic
nature of IL-10 has made translating the potential benefit of IL-10-
modulating therapies into the clinic difficult; however, strategies
designed to focus IL-10 expression onto antigen-specific T cells,
including SIT for allergic and autoimmune diseases, have shown
promising early results.
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